Iwaki M, Kobayashi T, Nogami A, Ogawa Y, Imajo K, Sakai E
BMJ Open. 2024; 14(11):e088862.
PMID: 39581726
PMC: 11590823.
DOI: 10.1136/bmjopen-2024-088862.
Ogino Y, Wakui N, Nagai H, Matsuda T
J Med Ultrason (2001). 2023; 50(2):187-195.
PMID: 36801991
DOI: 10.1007/s10396-023-01293-z.
Iwaki M, Kessoku T, Tanaka K, Ozaki A, Kasai Y, Yamamoto A
BMJ Open. 2022; 12(7):e060335.
PMID: 35820743
PMC: 9277396.
DOI: 10.1136/bmjopen-2021-060335.
Kawamura N, Imajo K, Kalutkiewicz K, Nagai K, Iwaki M, Kobayashi T
Hepatology. 2021; 76(1):186-195.
PMID: 34951726
PMC: 9307017.
DOI: 10.1002/hep.32302.
Ogino Y, Wakui N, Nagai H, Igarashi Y
JGH Open. 2021; 5(8):947-952.
PMID: 34386604
PMC: 8341177.
DOI: 10.1002/jgh3.12615.
Efficacy and safety of PERIOdontal treatment versus usual care for Nonalcoholic liver disease: protocol of the PERION multicenter, two-arm, open-label, randomized trial.
Kamata Y, Kessoku T, Shimizu T, Kobayashi T, Kurihashi T, Sato S
Trials. 2020; 21(1):291.
PMID: 32293522
PMC: 7092586.
DOI: 10.1186/s13063-020-4201-y.
Diagnostic value of MRI-PDFF for hepatic steatosis in patients with non-alcoholic fatty liver disease: a meta-analysis.
Gu J, Liu S, Du S, Zhang Q, Xiao J, Dong Q
Eur Radiol. 2019; 29(7):3564-3573.
PMID: 30899974
DOI: 10.1007/s00330-019-06072-4.
Will the magnetic resonance imaging proton density fat fraction replace liver biopsy as the gold standard for detecting steatosis?.
Yoneda M, Imajo K, Nakajima A
Hepatobiliary Surg Nutr. 2018; 7(4):292-293.
PMID: 30221157
PMC: 6131261.
DOI: 10.21037/hbsn.2018.04.02.
Clinical strategy of diagnosing and following patients with nonalcoholic fatty liver disease based on invasive and noninvasive methods.
Yoneda M, Imajo K, Takahashi H, Ogawa Y, Eguchi Y, Sumida Y
J Gastroenterol. 2017; 53(2):181-196.
PMID: 29177681
PMC: 5846871.
DOI: 10.1007/s00535-017-1414-2.
Coffee Intake Is Associated with a Lower Liver Stiffness in Patients with Non-Alcoholic Fatty Liver Disease, Hepatitis C, and Hepatitis B.
Hodge A, Lim S, Goh E, Wong O, Marsh P, Knight V
Nutrients. 2017; 9(1).
PMID: 28075394
PMC: 5295100.
DOI: 10.3390/nu9010056.
Pentraxin 3 Is a Predictor for Fibrosis and Arterial Stiffness in Patients with Nonalcoholic Fatty Liver Disease.
Ozturk K, Kurt O, Dogan T, Ozen A, Demirci H, Yesildal F
Gastroenterol Res Pract. 2016; 2016:1417962.
PMID: 26997950
PMC: 4779836.
DOI: 10.1155/2016/1417962.
Noninvasive biomarkers in non-alcoholic fatty liver disease: current status and a glimpse of the future.
Fitzpatrick E, Dhawan A
World J Gastroenterol. 2014; 20(31):10851-63.
PMID: 25152587
PMC: 4138464.
DOI: 10.3748/wjg.v20.i31.10851.
Soluble CD14 levels reflect liver inflammation in patients with nonalcoholic steatohepatitis.
Ogawa Y, Imajo K, Yoneda M, Kessoku T, Tomeno W, Shinohara Y
PLoS One. 2013; 8(6):e65211.
PMID: 23762319
PMC: 3676404.
DOI: 10.1371/journal.pone.0065211.
Noninvasive scoring systems in patients with nonalcoholic fatty liver disease with normal alanine aminotransferase levels.
Yoneda M, Imajo K, Eguchi Y, Fujii H, Sumida Y, Hyogo H
J Gastroenterol. 2012; 48(9):1051-60.
PMID: 23184095
DOI: 10.1007/s00535-012-0704-y.
Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2009 to 2010 in Japan: a multicenter large retrospective study.
Eguchi Y, Hyogo H, Ono M, Mizuta T, Ono N, Fujimoto K
J Gastroenterol. 2012; 47(5):586-95.
PMID: 22328022
DOI: 10.1007/s00535-012-0533-z.
Platelet count for predicting fibrosis in nonalcoholic fatty liver disease.
Yoneda M, Fujii H, Sumida Y, Hyogo H, Itoh Y, Ono M
J Gastroenterol. 2011; 46(11):1300-6.
PMID: 21750883
DOI: 10.1007/s00535-011-0436-4.
Plasma Pentraxin3 is a novel marker for nonalcoholic steatohepatitis (NASH).
Yoneda M, Uchiyama T, Kato S, Endo H, Fujita K, Yoneda K
BMC Gastroenterol. 2008; 8:53.
PMID: 19014569
PMC: 2621235.
DOI: 10.1186/1471-230X-8-53.
Type IV collagen 7s domain is an independent clinical marker of the severity of fibrosis in patients with nonalcoholic steatohepatitis before the cirrhotic stage.
Yoneda M, Mawatari H, Fujita K, Yonemitsu K, Kato S, Takahashi H
J Gastroenterol. 2007; 42(5):375-81.
PMID: 17530362
DOI: 10.1007/s00535-007-2014-3.
Accuracy of hyaluronic acid level for predicting liver fibrosis stages in patients with hepatitis C virus.
Halfon P, Bourliere M, Penaranda G, Deydier R, Renou C, Botta-Fridlund D
Comp Hepatol. 2005; 4:6.
PMID: 16008833
PMC: 1192814.
DOI: 10.1186/1476-5926-4-6.
